Further evaluation of bimolane and analogs as potential antitumor agents.
Bimolane has been shown to have good antitumor activity and on an equitoxic basis its activity is usually better than the chemically related razoxane. Resistance patterns of these two piperazinediones were similar. They exhibited cross-resistance to each other but little or no cross-resistance to most other clinically used drugs tested. Partial resistance was observed, however, between the piperazinediones and vincristine, daunorubicin and doxorubicin. The antitumor activities of three new analogs were compared with bimolane, ICRF-154 and razoxane against four rodent tumors. In general, bimolane was most effective.
D000818:Animals; D004351:Drug Resistance; D005260:Female; D007939:Leukemia L1210 / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D012516:Osteosarcoma / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use*; D011929:Razoxane / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D012510:Sarcoma 180 / Q000188:drug therapy
D010879:Piperazines; C031186:bimolane; D011929:Razoxane